Overview

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

Status:
Completed

Trial end date:
2014-10-16

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with normal renal function.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Pfizer

Treatments:

Ertugliflozin